Samples from GBM patients that were negative or only weakly stained (<50% of cells) for cleaved caspase-8 had worse cancer-specific overall survival (median was 8.5 months) than patients with tumors that highly expressed cleaved caspase-8 (median was 11.7 months; p = 0.0325), irrespective of clinical variables [69]. The gene discussed is CASP8; the disease is glioblastoma.